RADX
NASDAQ
$4.29
Radiopharm Theranostics Ltd (RADX)
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company is headquartered in Carlton, Australia.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $17.04 (+297.20%)
Market Cap
$36M
Beta (5Y)
0.45
Price Chart
Valuation
Market Cap$36M
P/S2.22
P/B1.13
Profitability
Total Revenue (TTM)$16M
Gross Profit (TTM)-$22M
EBITDA-$39M
Profit Margin-286.2%
Operating Margin-423.7%
EPS-$3.77
Growth & Risk
Beta (5Y)0.45
Sharpe Ratio0.54